Toll Free: 1-888-928-9744

Multiple Myeloma (Kahlers Disease) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 576 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014', provides an overview of the Multiple Myeloma (Kahler's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
Introduction 7
Multiple Myeloma (Kahler's Disease) Overview 8
Therapeutics Development 9
Multiple Myeloma (Kahler's Disease) - Therapeutics under Development by Companies 11
Multiple Myeloma (Kahler's Disease) - Therapeutics under Investigation by Universities/Institutes 20
Multiple Myeloma (Kahler's Disease) - Pipeline Products Glance 23
Multiple Myeloma (Kahler's Disease) - Products under Development by Companies 27
Multiple Myeloma (Kahler's Disease) - Products under Investigation by Universities/Institutes 37
Multiple Myeloma (Kahler's Disease) - Companies Involved in Therapeutics Development 39
Multiple Myeloma (Kahler's Disease) - Therapeutics Assessment 134
Drug Profiles 157
Multiple Myeloma (Kahler's Disease) - Recent Pipeline Updates 434
Multiple Myeloma (Kahler's Disease) - Dormant Projects 543
Multiple Myeloma (Kahler's Disease) - Discontinued Products 545
Multiple Myeloma (Kahler's Disease) - Product Development Milestones 546
Appendix 555

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify